BioSpace News Archive

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Stifel Healthcare Conference 2021, which will be webcast on November 16 at 8:20 a.m. P.T. / 11:20 a.m. E.T. David Meek, chief executive officer and Charles Baum, M.D., Ph.D., president, founder and head of research and development, will represent the company.

Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will present at the Jefferies London Healthcare Conference on November 17th, 2021 at 8:00am Eastern Time.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated a patent held by Mati Therapeutics, Inc. (Mati) relating to a drug delivery system containing dexamethasone.

CATHETRIX, an innovative developer of urinary smart catheter fixations, will present its new catheter stabilizer for prevention of UTIs and accidental Foley catheter extractions at MEDICA 2021, which will take place November 15–18 in Dusseldorf, Germany.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments.

Anavasi Diagnostics, a medical technology company focused on the development of novel molecular diagnostic testing using a proprietary patent-pending reverse transcriptase methodology, today announced it has been awarded $14.9 million from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative.

Lunaphore announced new research from collaborators at the University of Birmingham, who characterized the inflammatory response associated with a complication from maternal COVID-19 infection, using COMET™, Lunaphore’s all-in-one staining and imaging platform for high-throughput, hyperplex immunofluorescence.

Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis.

Predictive Health Diagnostics Company, Inc. (“PHDC” or “the Company”), a diagnostics platform company that develops, manufactures, and distributes specialty diagnostic tests combining science, technology, and proprietary analytics that detect diseases with significant unmet medical needs and support better therapeutic outcomes, today announced its acquisition of MUSE Microscopy.

TerSera Therapeutics LLC announced today the presentation of patient-reported clinical and productivity outcomes data from their registry trial (RELAX) in patients with carcinoid syndrome diarrhea (CSD) receiving treatment with Xermelo (telotristat ethyl).